Venaxis, Inc. to Present at Three Upcoming Investor Conferences

CASTLE ROCK, Colo., Sept. 5, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Rodman & Renshaw Annual Global Investment Conference, to be held September 8 10, 2013, at the Millennium Broadway Hotel in New York, the Craig-Hallum 4^th Annual Alpha Select Conference, to be held September 26, 2013, at the Convene 730 3^rd Avenue in New York; as well as the Aegis Capital Vegas Healthcare Conference, to be held September 26 28, 2013, at the Wynn Las Vegas Hotel.

Steve Lundy, President and CEO of Venaxis, will provide an overview of the Company’s business at the Rodman & Renshaw and Craig-Hallum Conferences, and Don Hurd, Senior Vice President and Chief Commercial Officer of Venaxis, will present at the Aegis Capital Conference. Mr. Lundy and Mr. Hurd will be available to participate in one-on-one meetings with investors who are registered to attend the respective conferences.

The Rodman & Renshaw presentation will be webcast. To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com. The webcast replay will remain available for 90 days following each live presentation.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company’s rapid, protein biomarker-based assay for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries. For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes “forward-looking statements” of Venaxis, Inc. (“Venaxis”) as defined by the Securities and Exchange Commission (“SEC”). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1Test at a profitable price point, execute agreements required to successfully advance the company’s objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis’ recent filings with the SEC, including its Form 10-Q for the quarter ended June 30, 2013.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD
jdrumm@tiberend.com; (212) 375-2664

Claire Sojda
csojda@tiberend.com; (212) 375-2686

SOURCE Venaxis, Inc.